STAT3 inhibitor BBI608 reduces patient-specific primary cell viability of cervical and endometrial cancer at a clinical-relevant concentration
Jing Chen(Zhejiang Institute of Special Equipment Inspection), Mubiao Liu(Zhuhai People's Hospital), Jiemei Hu(Guangdong Academy of Medical Sciences), Huawen Li(Jinan University), Haishan Zeng(University of British Columbia), Pengfei Deng(Jinan University), Yanchun Lin, Yun Li(Dali University), Ting Song(Jinan University), Huihua Cai(Guangdong Academy of Medical Sciences), Haoyu Zeng(Guangdong Academy of Medical Sciences), Tian Guan(Shanghai Jiao Tong University), Shuting Huang(Taishan University)
Cited by 10
Related Papers
Recent advances in therapeutic strategies for triple-negative breast cancer
|Journal of Hematology & Oncology|2022|892
Near‐infrared Raman spectroscopy for optical diagnosis of lung cancer
|International Journal of Cancer|2003|811
Genomic Profiling of Adult and Pediatric B-cell Acute Lymphoblastic Leukemia
|EBioMedicine|2016|345
Synthesis and anticancer evaluation of bis(benzimidazoles), bis(benzoxazoles), and benzothiazoles
|Bioorganic & Medicinal Chemistry|2006|342
Transcriptional landscape of B cell precursor acute lymphoblastic leukemia based on an international study of 1,223 cases
|Proceedings of the National Academy of Sciences|2018|324